Recombination and drug resistance in HIV: Population dynamics and stochasticity

Epidemics

Volumn 1, Issue 1, 2009, Pages 58-69

  Kouyos, Roger D ^a   Fouchet, David ^a   Bonhoeffer, Sebastian ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Drug resistance; HIV; Population dynamics; Recombination

Indexed keywords

ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; POPULATION DYNAMICS; POPULATION GENETICS; PRIORITY JOURNAL; PROBABILITY; STOCHASTIC MODEL; VIRUS RECOMBINATION; VIRUS RESISTANCE;

DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; MODELS, GENETIC; MUTATION; POPULATION DYNAMICS; RECOMBINATION, GENETIC; STOCHASTIC PROCESSES;

EID: 63149115427     PISSN: 17554365     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.epidem.2008.11.001     Document Type: Article

References (33)

1. Achaz G., Palmer S., Kearney M., Maldarelli F., Mellors J.W., et al. A robust measure of HIV-1 population turnover within chronically infected individuals. Mol. Biol. Evol. 21 (2004) 1902-1912
2. Althaus C.L., and Bonhoeffer S. Stochastic interplay between mutation and recombination during the acquisition of drug resistance mutations in human immunodeficiency virus type 1. J. Virol. 79 (2005) 13572-13578
3. Bartlett J.A. Addressing the challenges of adherence. J. Acquir. Immune Defic. Syndr. 29 Suppl 1 (2002) S2-S10
4. Boerlijst M.C., Bonhoeffer S., and Nowak M.A. Viral quasi-species and recombination. Proc. R. Soc. Lond., B Biol. Sci. 263 (1996) 1577-1584
5. Bonhoeffer S., Chappey C., Parkin N.T., Whitcomb J.M., and Petropoulos C.J. Evidence for positive epistasis in HIV-1. Science 306 (2004) 1547-1550
6. Bretscher M.T., Althaus C.L., Muller V., and Bonhoeffer S. Recombination in HIV and the evolution of drug resistance: for better or for worse?. Bioessays 26 (2004) 180-188
7. Burke D.S. Recombination in HIV: an important viral evolutionary strategy. Emerg Infect Dis 3 (1997) 253-259
8. Carvajal-Rodriguez A., Crandall K.A., and Posada D. Recombination favors the evolution of drug resistance in HIV-1 during antiretroviral therapy. Infection Genetics and Evolution 7 (2007) 476-483
9. Elena S.F., and Lenski R.E. Test of synergistic interactions among deleterious mutations in bacteria. Nature 390 (1997) 395-398
10. Fraser C. HIV recombination: what is the impact on antiretroviral therapy?. J. R. Soc. Interface 2 (2005) 489-503
11. Funk G.a., Fischer M., Joos B., Opravil M., Gunthard H.F., et al. Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells. J. Acquir. Immune Defic. Syndr. 26 (2001) 397-404
12. Gillespie D.T. Approximate accelerated stochastic simulation of chemically reacting systems. J. Chem. Phys. 115 (2001) 1716-1733
13. Ho D.D., Neumann a.U., Perelson a.S., Chen W., Leonard J.M., et al. Rapid turnover of plasma virions and Cd4 lymphocytes in Hiv-1 infection. Nature 373 (1995) 123-126
14. Jung A., Maier R., Vartanian J.P., Bocharov G., Jung V., et al. Multiply infected spleen cells in HIV patients. Nature 418 (2002) 144
15. Kouyos R.D., Althaus C.L., and Bonhoeffer S. Stochastic or deterministic: what is the effective population size of HIV-1?. Trends Microbiol. 14 (2006) 507-511
16. Leigh Brown A.J. Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 1862-1865
17. Levy D.N., Aldrovandi G.M., Kutsch O., and Shaw G.M. Dynamics of HIV-1 recombination in its natural target cells. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4204-4209
18. Mansky L.M., and Temin H.M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69 (1995) 5087-5094
19. Mansky L.M., and Temin H.M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69 (1995) 5087-5094
20. Nijhuis M., Boucher C.A., Schipper P., Leitner T., Schuurman R., et al. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 14441-14446
21. Nowak M.A., Lloyd A.L., Vasquez G.M., Wiltrout T.A., Wahl L.M., et al. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J. Virol. 71 (1997) 7518-7525
22. Otto S.P., and Barton N.H. Selection for recombination in small populations. Evolution 55 (2001) 1921-1931
23. Otto S.P., and Lenormand T. Resolving the paradox of sex and recombination. Nat. Rev. Genet. 3 (2002) 252-261
24. Perelson A.S., Essunger P., Cao Y.Z., Vesanen M., Hurley A., et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387 (1997) 188-191
25. Ramratnam B., Bonhoeffer S., Binley J., Hurley A., Zhang L.Q., et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 354 (1999) 1782-1785
26. Ribeiro R.M., and Bonhoeffer S. Production of resistant HIV mutants during antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 7681-7686
27. Rodrigo A.G., Shpaer E.G., Delwart E.L., Iversen A.K., Gallo M.V., et al. Coalescent estimates of HIV-1 generation time in vivo. Proc. Natl. Acad. Sci U. S. A. 96 (1999) 2187-2191
28. Rouzine I.M., and Coffin J.M. Linkage disequilibrium test implies a large effective population number for HIV in vivo. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 10758-10763
29. Seo T.K., Thorne J.L., Hasegawa M., and Kishino H. Estimation of effective population size of HIV-1 within a host: a pseudomaximum-likelihood approach. Genetics 160 (2002) 1283-1293
30. Shriner D., Shankarappa R., Jensen M.A., Nickle D.C., Mittler J.E., et al. Influence of random genetic drift on human immunodeficiency virus type 1 env evolution during chronic infection. Genetics 166 (2004) 1155-1164
31. Tian T.H., and Burrage K. Binomial leap methods for simulating stochastic chemical kinetics. J. Chem. Phys. 121 (2004) 10356-10364
32. Wahl L.M., and Nowak M.A. Adherence and drug resistance: predictions for therapy outcome. Proc. R. Soc. Lond., B Biol. Sci. 267 (2000) 835-843
33. Wei X.P., Ghosh S.K., Taylor M.E., Johnson V.a., Emini E.a., et al. Viral dynamics in human-immunodeficiency-virus type-1 infection. Nature 373 (1995) 117-122